JARID2 (NM_004973) Human Untagged Clone

SKU
SC309940
JARID2 (untagged)-Human jumonji, AT rich interactive domain 2 (JARID2)
  $1,194.00
3 Weeks*
Specifications
Specifications
Product Data
Type Human Untagged Clone
Target Symbol JARID2
Synonyms JMJ
Vector pCMV6-Entry
E. coli Selection Kanamycin (25 ug/mL)
Mammalian Cell Selection Neomycin
Sequence Data
Fully Sequenced ORF
>SC309940 representing NM_004973.
Blue=Insert sequence Red=Cloning site Green=Tag(s)

GCTCGTTTAGTGAACCGTCAGAATTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTG
GATCCGGTACCGAGGAGATCTGCCGCCGCGATCGCC
ATGAGCAAGGAAAGACCCAAGAGGAATATCATTCAGAAGAAATACGATGACAGTGATGGGATTCCGTGG
TCAGAAGAACGGGTGGTACGTAAAGTCCTTTATTTGTCTCTGAAGGAGTTCAAGAATTCCCAGAAGAGG
CAGCATGCGGAAGGCATTGCTGGGAGCCTGAAAACTGTGAATGGGCTCCTTGGTAATGACCAGTCTAAG
GGATTAGGACCAGCATCAGAACAGTCAGAGAATGAAAAGGACGATGCATCCCAAGTGTCCTCCACTAGC
AACGATGTTAGTTCTTCAGATTTTGAAGAAGGGCCGTCGAGGAAAAGGCCCAGGCTGCAAGCACAAAGG
AAGTTTGCTCAGTCTCAGCCGAATAGTCCCAGCACAACTCCAGTAAAGATAGTGGAGCCATTGCTACCC
CCTCCAGCTACTCAGATATCAGACCTCTCTAAAAGGAAGCCTAAGACAGAAGATTTTCTTACCTTTCTC
TGCCTTCGAGGTTCTCCTGCGCTGCCCAACAGCATGGTGTATTTTGGAAGCTCTCAGGATGAGGAGGAA
GTCGAGGAGGAAGATGATGAGACAGAAGACGTCAAAACAGCCACCAACAATGCTTCATCTTCATGCCAG
TCGACCCCCAGGAAAGGAAAAACCCACAAACATGTTCACAACGGGCATGTTTTCAATGGTTCCAGCAGG
TCAACACGGGAGAAGGAACCTGTTCAAAAACACAAAAGCAAAGAGGCCACTCCCGCAAAGGAGAAGCAC
AGCGATCACCGGGCTGACAGCCGCCGGGAGCAGGCTTCAGCTAACCACCCCGCAGCGGCCCCCTCCACG
GGTTCCTCGGCCAAGGGGCTTGCTGCCACCCATCACCACCCCCCTCTGCATCGGTCGGCTCAGGACTTA
CGGAAACAGGTTTCTAAGGTAAACGGAGTCACTCGAATGTCATCTCTGGGTGCAGGTGTAACCAGTGCC
AAAAAGATGCGCGAGGTCAGACCTTCACCATCCAAAACTGTGAAGTACACTGCCACGGTGACGAAGGGG
GCTGTCACATACACCAAAGCCAAGAGAGAACTGGTCAAGGACACCAAACCCAATCACCACAAGCCCAGT
TCCGCTGTCAACCACACAATCTCAGGGAAAACTGAAAGTAGCAATGCAAAAACCCGCAAACAGGTGCTA
TCCCTCGGGGGGGCGTCCAAGTCCACTGGGCCCGCCGTCAATGGCCTCAAGGTCAGTGGCAGGTTGAAC
CCAAAGTCATGCACTAAGGAGGTGGGGGGGCGGCAGCTGCGGGAGGGCCTGCAGCTGCGGGAGGGGCTG
CGGAACTCCAAGAGGAGACTGGAAGAGGCACACCAGGCGGAGAAGCCGCAGTCGCCCCCCAAGAAGATG
AAAGGGGCGGCTGGCCCCGCCGAAGGCCCTGGCAAGAAGGCCCCGGCCGAGAGAGGTCTGCTGAACGGA
CACGTGAAGAAGGAAGTGCCGGAGCGCAGTCTGGAGAGGAATCGGCCGAAGCGGGCCACGGCCGGGAAG
AGCACGCCAGGCAGACAAGCACATGGCAAGGCGGACAGCGCCTCCTGTGAAAATCGTTCTACCTCGCAA
CCGGAGTCCGTGCACAAGCCGCAGGACTCGGGCAAGGCCGAGAAGGGCGGCGGCAAGGCCGGGTGGGCG
GCCATGGACGAGATCCCCGTCCTCAGGCCCTCCGCCAAGGAGTTCCACGATCCGCTCATCTACATCGAG
TCGGTCCGCGCTCAGGTGGAGAAGTTCGGGATGTGCAGGGTGATCCCCCCTCCGGACTGGCGGCCCGAG
TGCAAGCTCAACGATGAGATGCGGTTTGTCACGCAGATTCAGCACATCCACAAGCTGGGCCGGCGCTGG
GGCCCCAACGTGCAGCGGCTGGCCTGCATCAAGAAGCACCTCAAATCTCAGGGCATCACCATGGACGAG
CTCCCGCTCATAGGGGGCTGTGAGCTCGACCTGGCCTGCTTTTTCCGGCTGATTAATGAGATGGGCGGC
ATGCAGCAAGTGACTGACCTCAAAAAATGGAACAAACTAGCAGACATGCTGCGCATCCCCAGAACTGCC
CAGGACCGGCTGGCCAAGCTGCAGGAGGCCTACTGCCAGTACCTACTCTCCTACGACTCCCTGTCCCCA
GAGGAGCACCGGCGGCTGGAGAAGGAGGTGCTGATGGAGAAGGAGATCCTGGAGAAGCGCAAGGGGCCG
CTGGAAGGCCACACAGAGAACGACCACCACAAGTTCCACCCTCTGCCCCGCTTCGAGCCCAAGAATGGG
CTCATCCACGGCGTGGCCCCCAGGAACGGCTTCCGCAGCAAGCTCAAGGAGGTGGGCCAGGCCCAGTTG
AAGACTGGCCGGCGGCGACTCTTCGCTCAGGAAAAAGAAGTGGTCAAGGAAGAGGAGGAGGACAAAGGC
GTCCTCAATGACTTCCACAAGTGCATCTATAAGGGAAGGTCTGTTTCTCTAACAACTTTTTATCGAACA
GCGAGGAATATCATGAGCATGTGTTTCAGCAAGGAGCCTGCCCCAGCCGAAATCGAGCAAGAGTACTGG
AGGCTAGTGGAAGAGAAGGACTGCCACGTGGCAGTGCACTGCGGCAAGGTGGACACCAACACTCACGGC
AGTGGATTCCCAGTAGGAAAATCAGAACCCTTTTCGAGGCATGGATGGAACCTCACCGTCCTCCCCAAT
AACACAGGGTCCATCCTGCGTCACCTCGGTGCTGTGCCTGGAGTGACTATTCCCTGGCTAAATATTGGC
ATGGTCTTTTCTACCTCATGCTGGTCTCGAGACCAAAATCACCTTCCATACATTGACTACTTACACACT
GGTGCTGACTGCATTTGGTATTGCATTCCTGCTGAGGAGGAGAACAAGCTGGAAGATGTGGTCCACACC
CTGCTGCAAGCCAATGGCACCCCAGGGCTGCAGATGCTGGAAAGCAACGTCATGATCTCCCCGGAGGTG
CTGTGCAAAGAGGGGATCAAGGTGCACAGGACCGTGCAGCAGAGTGGCCAGTTTGTCGTCTGCTTCCCG
GGATCCTTTGTGTCCAAAGTGTGCTGTGGGTACAGCGTGTCTGAAACCGTGCACTTTGCTACCACCCAG
TGGACAAGTATGGGCTTTGAGACCGCCAAGGAAATGAAGCGTCGCCATATAGCTAAGCCATTCTCCATG
GAGAAGTTACTCTACCAGATTGCACAAGCAGAAGCAAAAAAAGAAAACGGTCCCACTCTCAGTACCATC
TCAGCCCTCCTGGATGAGCTCAGGGATACAGAGCTGCGGCAGCGCAGGCAGCTGTTCGAGGCTGGCCTC
CACTCCTCCGCACGCTATGGCAGCCACGATGGCAGCAGCACGGTGGCGGACGGGAAGAAAAAGCCTCGA
AAGTGGCTGCAGTTGGAGACGTCAGAGAGGAGGTGTCAGATCTGCCAGCACCTGTGCTACCTGTCCATG
GTGGTACAAGAGAACGAAAACGTCGTGTTCTGTCTGGAGTGTGCTCTGCGCCACGTGGAGAAACAGAAG
TCCTGCCGAGGGCTGAAGTTGATGTACCGCTACGATGAGGAACAGATTATCAGTCTGGTCAATCAGATC
TGCGGCAAAGTGTCTGGTAAAAACGGCAGCATTGAGAACTGTCTCAGTAAACCCACACCAAAAAGAGGT
CCCCGCAAGAGAGCGACAGTGGACGTGCCCCCCTCCCGTCTGTCAGCCTCCAGTTCATCCAAAAGTGCT
TCGAGCTCATCATGA

ACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGAT
TACAAGGATGACGACGATAAG
GTTTAAACGGCCGGC
Restriction Sites SgfI-MluI |
ACCN NM_004973
Insert Size 3741 bp
OTI Disclaimer Our molecular clone sequence data has been matched to the reference identifier above as a point of reference. Note that the complete sequence of our molecular clones may differ from the sequence published for this corresponding reference, e.g., by representing an alternative RNA splicing form or single nucleotide polymorphism (SNP).
OTI Annotation This TrueClone is provided through our Custom Cloning Process that includes sub-cloning into OriGene's pCMV6 vector and full sequencing to provide a non-variant match to the expected reference without frameshifts, and is delivered as lyophilized plasmid DNA.
Components The ORF clone is ion-exchange column purified and shipped in a 2D barcoded Matrix tube containing 10ug of transfection-ready, dried plasmid DNA (reconstitute with 100 ul of water).
Reconstitution Method 1. Centrifuge at 5,000xg for 5min.
2. Carefully open the tube and add 100ul of sterile water to dissolve the DNA.
3. Close the tube and incubate for 10 minutes at room temperature.
4. Briefly vortex the tube and then do a quick spin (less than 5000xg) to concentrate the liquid at the bottom.
5. Store the suspended plasmid at -20°C. The DNA is stable for at least one year from date of shipping when stored at -20°C.
Note Plasmids are not sterile.  For experiments where strict sterility is required, filtration with 0.22um filter is required.
Shipping Ambient
Reference Data
RefSeq NM_004973.3
RefSeq Size 6112 bp
RefSeq ORF 3741 bp
Locus ID 3720
UniProt ID Q92833
Cytogenetics 6p22.3
Domains ARID, JmjC, JmjN, zf-C5HC2
Protein Families Transcription Factors
MW 138.7 kDa
Summary This gene encodes a Jumonji- and AT-rich interaction domain (ARID)-domain-containing protein. The encoded protein is a DNA-binding protein that functions as a transcriptional repressor. This protein interacts with the Polycomb repressive complex 2 (PRC2) which plays an essential role in regulating gene expression during embryonic development. This protein facilitates the recruitment of the PRC2 complex to target genes. Alternate splicing results in multiple transcript variants. Mutations in this gene are associated with chronic myeloid malignancies. provided by RefSeq, May 2012
Transcript Variant: This variant (1) represents the longer transcript and encodes the longer isoform (1). Sequence Note: This RefSeq record was created from transcript and genomic sequence data to make the sequence consistent with the reference genome assembly. The genomic coordinates used for the transcript record were based on transcript alignments.
Reviews
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources
"NM_004973" in other vectors (6)
SKU Description Size Price
RC207885 JARID2 (Myc-DDK-tagged)-Human jumonji, AT rich interactive domain 2 (JARID2) 10 ug
$589.00 $1,085.00
RC207885L1 Lenti-ORF clone of JARID2 (Myc-DDK-tagged)-Human jumonji, AT rich interactive domain 2 (JARID2) 10 ug
$1,385.00
RC207885L2 Lenti-ORF clone of JARID2 (mGFP-tagged)-Human jumonji, AT rich interactive domain 2 (JARID2) 10 ug
$1,385.00
RC207885L3 Lenti-ORF clone of JARID2 (Myc-DDK-tagged)-Human jumonji, AT rich interactive domain 2 (JARID2) 10 ug
$1,385.00
RC207885L4 Lenti-ORF clone of JARID2 (mGFP-tagged)-Human jumonji, AT rich interactive domain 2 (JARID2) 10 ug
$1,385.00
RG207885 JARID2 (tGFP-tagged) - Human jumonji, AT rich interactive domain 2 (JARID2) 10 ug
$789.00 $1,285.00

file-alt Citations

Jarid2 enhances the progression of bladder cancer through regulating PTEN/AKT signaling
Wang, Lyu, Ji et al
Life Sci. (2019) 230, 162-168 DOI: 10.1016/j.lfs.2019.05.053
AI Summary: OriGene products, including the Jarid2 shRNA plasmid (TL312055), Jarid2 overexpression plasmid (OE-Jarid2; SC309940), and PTEN siRNA (si-PTEN; SR321496), were used to modulate gene expression and investigate the roles of Jarid2 and PTEN in bladder cancer progression via PTEN/AKT signaling in this study.
Snippet: Jumonji AT-rich interactive domain 2 (Jarid2) is an interacting component of PRC2 which catalyzes methylation of H3K27 (H3K27me3) and causes the downregulation of PTEN. In the present study, we aimed to explore whether Jarid2 could interact with H3K27me3 to regulate PTEN expression in bladder cancer. Jarid2 expression in bladder cancer tissues and cells were determined by western blotting and RT-PCR. … Chromatin immunoprecipitation (ChIP) assay was used to assess the methylation of PTEN. Jarid2 expression was increased in bladder cancer tissues and cells. Downregulation of Jarid2 with shRNA transfection obviously inhibited the proliferation, migration and tumorigenesis of bladder cancer T24 and HT-1376 cells and induced cell apoptosis. Jarid2 downregulation decreased the expression of p-AKT and increased PTEN expression. Besides, Jarid2 down-regulation repressed the epithelial-mesenchymal transition (EMT), whereas knockdown of PTEN impaired this effect. Moreover, upregulation of Jarid2 increased the combination of PTEN promoter and H3K27me3, and 5-aza-CdR rescued it. Meanwhile, 5-aza-CdR administration abolished Jarid2 roles in the promotion of EMT process and AKT activation, as well as the reduction of PTEN expression. Overall, the present study elaborated that Jarid2 facilitated the progression of bladder cancer through H3K27me3-mediated PTEN downregulation and AKT activation, which might provide a new mechanism for Jarid2 in promoting bladder cancer progression. … All rights reserved.;TL312055), and the overexpressing plasmid of Jarid2 (OE-Jarid2;No. SC309940), and the small interfering RNAs (siRNAs) used to downregulate PTEN (si-PTEN, No. SR321496), as well as their negative controls (NC) were all purchased from OriGene (Beijing, China;Jumonji AT-rich interactive domain 2 (Jarid2) is an interacting component of PRC2 which catalyzes methylation of H3K27 (H3K27me3) and causes the downregulation of PTEN. In the present study, we aimed to explore whether Jarid2 could interact with H3K27me3 to regulate PTEN expression in bladder cancer. Jarid2 expression in bladder cancer tissues and cells were determined by western blotting and RT-PCR. … Chromatin immunoprecipitation (ChIP) assay was used to assess the methylation of PTEN. Jarid2 expression was increased in bladder cancer tissues and cells. Downregulation of Jarid2 with shRNA transfection obviously inhibited the proliferation, migration and tumorigenesis of bladder cancer T24 and HT-1376 cells and induced cell apoptosis. Jarid2 downregulation decreased the expression of p-AKT and increased PTEN expression. Besides, Jarid2 down-regulation repressed the epithelial-mesenchymal transition (EMT), whereas knockdown of PTEN impaired this effect. Moreover, upregulation of Jarid2 increased the combination of PTEN promoter and H3K27me3, and 5-aza-CdR rescued it. Meanwhile, 5-aza-CdR administration abolished Jarid2 roles in the promotion of EMT process and AKT activation, as well as the reduction of PTEN expression. Overall, the present study elaborated that Jarid2 facilitated the progression of bladder cancer through H3K27me3-mediated PTEN downregulation and AKT activation, which might provide a new mechanism for Jarid2 in promoting bladder cancer progression. …
Showing 1-1 of 1 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products